HD-OPM Archive
Topics › Lp(a)

Statins cut heart attack and stroke risk in high Lp(a) despite raising it 5-20%

Louis Nervegna · Jun 20, 2026 · ♥ 11 reactions · 7 comments · original Facebook post
Lp(a)StatinsLDL, ApoB & lipid panel
AI summary & key facts

Louis explains that Lp(a) carries LDL cholesterol and sticks in artery walls, so lowering total LDL-C with statins cancels much of the risk from high Lp(a). Meta-analyses show statins raise Lp(a) 5-20%, but a Stanford expert argues this is clinically unimportant given the outcome benefit across 25 randomized trials.

Statins are proven to lower risk of heart attacks, strokes, and cardiovascular mortality in people with high Lp(a).

Lp(a) lipoproteins carry LDL cholesterol. That is their primary cargo. This is the same LDL cholesterol that is reported on a standard lipid panel as LDL-C.

The main reason why Lp(a) is so dangerous is because it deposits LDL-C cholesterol inside the walls of your arteries. The apo(a) protein on the Lp(a) particle makes it particularly sticky inside the artery wall, leading to the LDL-C cholesterol getting trapped. It is this trapped LDL-C cholesterol that leads to the formation of plaques. The apo(a) protein is also prothrombotic and makes blood clots form more easily, if a plaque should happen to rupture.

See this post for more explanation of this: ↪ Lp(a) carries LDL cholesterol, so LDL-C on a lab report includes Lp(a) cholesterol

The fact that Lp(a) carries LDL-C cholesterol is a major reason why getting your total blood level of LDL cholesterol (LDL-C) low with statins helps to cancel a lot of the risk from high Lp(a). There is less total LDL-C cholesterol to get stuck inside your arteries, even if a lot of that LDL-C cholesterol is still coming from Lp(a).

Research cited

Statins and Lp(a)

Meta-analyses of randomized controlled trials have shown that statins can raise Lp(a) levels by as much as 5-20%.

For example:

Paper · European Heart JournalEuropean Heart Journal articleacademic.oup.com

In this video, Joshua Knowles MD, PhD— a professor of cardiovascular medicine at Stanford University— explains why this does not matter clinically. Knowles is a world-renowned expert on genetic causes of high cholesterol, including high Lp(a). Knowles explains that statins are an important part of the treatment for patients with genetically high Lp(a).

Bio of Joshua Knowles:

CAP ProfilesJoshua W. Knowles | Stanford Medicinemed.stanford.edu

As Knowles alludes to in the video, there are over 25 large long-running randomized controlled trials that have demonstrated that statins lower risk for heart attacks and strokes. This includes people with high Lp(a).

↪ 25 statin RCTs: about 75 mg/dL LDL lowering cut heart attack and stroke roughly 40%

Combining data from all these 25 trials:

Lowering LDL by about 75mg/dL (1.9mmol/L) with a statin reduces the risk of having a heart attack or stroke (MACE) by about 40% on average, as compared to people taking a placebo.

7 of these 25 clinical trials were primary prevention trials— participants who never had a heart attack or stroke before. The risk reductions for the 7 primary prevention trials were even larger than the risk reductions for the 18 secondary prevention trials.

Reference for risk reduction from the 25 statin trials:
↪ 25 statin RCTs: about 75 mg/dL LDL lowering cut heart attack and stroke roughly 40%

#statinslpaHD #statinsHD #lpaHD

← newer: Big swings in Lp(a) usually reflect acute inflammation, not older: Stanford Medicine fiber facts: most people fall short of rec →